Anika Therapeutics (STU:AKP) Shares Outstanding (Basic Average): 13.53 Mil (As of Mar. 2026)


STU:AKP Anika Therapeutics Inc STU:AKP
63 GF Score
Price €12.80
GF Value €17.96
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is Anika Therapeutics Shares Outstanding (Basic Average)?

Anika Therapeutics STU:AKP +5.79% 63 Shares Outstanding (Basic Average) is 13.53 Mil as of Mar. 2026. GuruFocus rates STU:AKP with a GF Score™ of 63/100 and a GF Value™ of €17.96 (Modestly Undervalued). The stock has 4 warning signs investors should review.

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. Anika Therapeutics's average basic shares outstanding for the quarter that ended in Mar. 2026 was 13.53 Mil.


Anika Therapeutics  (STU:AKP) Shares Outstanding (Basic Average) Explanation

A company may buy back shares or issue shares in any fiscal period. If a company buys back shares, we should observe that the total number of shares decline. If the company issues new shares, the number of shares outstanding increases.


Be Aware

Usually the presence of treasury shares and a history of buyback are good indicators that company has competitive advantage. But studies have shown that companies usually buy back at wrong time. Buying back shares below its intrinsic value increases value for remaining shareholders. Buying back overvalued shares destroys value for existing shareholders.


Anika Therapeutics Shares Outstanding (Basic Average) Related Terms


Anika Therapeutics Shares Outstanding (Basic Average) Historical Data

* Premium members only.

The historical data trend for Anika Therapeutics's Shares Outstanding (Basic Average) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Anika Therapeutics Shares Outstanding (Basic Average) Chart

Anika Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Shares Outstanding (Basic Average)
Get a 7-Day Free Trial Premium Member Only Premium Member Only 14.40 14.56 14.66 14.72 14.34

Anika Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Shares Outstanding (Basic Average) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 14.30 14.36 14.42 14.27 13.53
STU:AKP
63GF Score
Anika Therapeutics Inc STU:AKP
Shares Outstanding (Basic Average) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Anika Therapeutics Shares Outstanding (Basic Average) Calculation

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. They have voting rights and represent ownership in the corporation by the person that holds the shares. They should be distinguished from treasury shares, which are shares held by the corporation itself, having no exercisable rights.

Shares outstanding can be calculated as either basic or fully diluted. The fully diluted shares outstanding count includes diluting securities, such as options, warrants or convertibles.

Please note: GuruFocus named Shares Outstanding (EOP) is the shares for that exact time point. It is usually used to calculate balance sheet related items, such as Book Value per Share, etc. While Shares Outstanding (Diluted Average) and Shares Outstanding (Basic Average) are the weighted average shares over a period of time (a year, a quarter, or so). They are usually used to calculate income statement or cashflow statement related items, such as Earnings per Share (Diluted), etc.

What does a Shares Outstanding (Basic Average) of 13.53 Mil mean?
Anika Therapeutics (STU:AKP) has a Shares Outstanding (Basic Average) of 13.53 Mil as of Mar. 2026. The average shares outstanding over two periods not accounting for dilutive securities like convertible bonds. View historical data on Anika Therapeutics and its competitors.
Is Anika Therapeutics' Shares Outstanding (Basic Average) too high?
Anika Therapeutics' current Shares Outstanding (Basic Average) is 13.53 Mil. Overall, Anika Therapeutics has a GF Score™ of 63/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Anika Therapeutics' Shares Outstanding (Basic Average) compare to LFCR and NIKA?
Anika Therapeutics' Shares Outstanding (Basic Average) of 13.53 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Shares Outstanding (Basic Average) for a Drug Manufacturers company?
A good Shares Outstanding (Basic Average) depends on the Drug Manufacturers industry context. However, Shares Outstanding (Basic Average) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Shares Outstanding (Basic Average) mean?
A high Shares Outstanding (Basic Average) can signal that a stock is expensive relative to its fundamentals. The average shares outstanding over two periods not accounting for dilutive securities like convertible bonds. View historical data on Anika Therapeutics and its competitors. Anika Therapeutics's current Shares Outstanding (Basic Average) is 13.53 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Anika Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Anika Therapeutics (STU:AKP) is currently considered Modestly Undervalued. The stock's GF Value™ is €17.96, compared to a current price of €12.80 — trading 28.7% below its estimated fair value. The current Shares Outstanding (Basic Average) is 13.53 Mil. Anika Therapeutics' overall GF Score™ is 63/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Shares Outstanding (Basic Average) calculated?
Shares Outstanding (Basic Average) is calculated from a company's financial statements. For Anika Therapeutics (STU:AKP), the current Shares Outstanding (Basic Average) is 13.53 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Anika Therapeutics (STU:AKP) Overvalued in 2026?

Based on GuruFocus' analysis, Anika Therapeutics stock appears to be undervalued. The current stock price of €12.80 is trading 28.7% below its estimated GF Value™ of €17.96. GuruFocus considers Anika Therapeutics to be Modestly Undervalued.

Key valuation signals for STU:AKP:

  • Shares Outstanding (Basic Average): 13.53 Mil
  • GF Value™: €17.96 vs. price of €12.80 (28.7% below fair value)
  • GF Score™: 63/100 with 4 warning signs

No single metric tells the full story. See the STU:AKP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Anika Therapeutics Business Description

Other Exchanges ANIK:USA
Address 32 Wiggins Avenue, Bedford, MA, USA, 01730
Anika Therapeutics Inc operates in the OA Pain Management and regenerative solutions space, focusing on early intervention orthopedics. The company leverages proprietary hyaluronic acid (HA) technology to develop differentiated products and provides products and services. Its OA Pain Management products include Orthovisc, Monovisc, and Cingal. Monovisc and Orthovisc are single- and multi-injection HA viscosupplement products indicated for pain relief from OA conditions and are generally administered to patients in an office setting. In the United States, Monovisc and Orthovisc are marketed exclusively by Johnson & Johnson MedTech. It generates maximum revenue from the OEM Channel and derives the majority of its revenue from the United States, with a presence in Europe and other countries.
63GF Score

Get the complete analysis for STU:AKP

Shares Outstanding (Basic Average) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€12.80
Price
€17.96
GF Value